HARROW INC
HROWNASDAQTrading Snapshot
- Day Range
- $643.86 – $650.66
- 52-Week Range
- $28.54 – $54.85
- Volume
- $2.52B
- Avg Volume
- $2.20B
- Shares Outstanding
- 37.3M
- Next Earnings
- Oct 24, 2026
Fundamentals Snapshot
- Annual Revenue
- $272M
- Last Q Revenue
- $71M
- P/E Ratio
- —
- P/S Ratio
- 4.3x
- EPS (TTM)
- $-1.00
- Dividend Yield
- —
- Dilution (1yr)
- +2.7%
Why Investors Own HROW
- ✓High-growth profile — revenue up +1.3% YoY with expanding US Equity exposure.
- ✓Healthy economics — 39% gross margin and 8% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
HARROW INC
HROW
StockOtter · stockotter.spaceAbout HARROW INC
Harrow Health, Inc. operates as a healthcare enterprise with a specialized focus on ophthalmic solutions. The company's portfolio includes ImprimisRx, a business dedicated to ophthalmology outsourcing and pharmaceutical compounding, as well as DEXYCU, a product utilized for managing post-operative inflammation. Beyond its direct offerings, Harrow Health maintains equity investments in several pharmaceutical ventures. These encompass Surface Ophthalmics, Inc., a clinical-stage firm actively developing and commercializing therapeutic agents for ocular surface diseases; Melt Pharmaceuticals, Inc., another clinical-stage entity concentrating on proprietary non-intravenous sedation and anesthesia treatments for various medical procedures conducted in hospital, outpatient, and office environments; and Eton Pharmaceuticals, Inc., a commercial-stage company involved in the creation and market launch of drug products. Moreover, Harrow Health holds royalty interests in four investigational drug candidates currently being advanced by Surface Ophthalmics, Inc. and Melt Pharmaceuticals, Inc. The company, initially incorporated in 2006 and based in San Diego, California, underwent a name change from Imprimis Pharmaceuticals, Inc. to Harrow Health, Inc. in December 2018.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Price Target
ⓘLatest News & Updates
HARROW INC tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
Analysts lift HROW price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
HARROW INC announces new agreement to expand its footprint
The move broadens the company’s reach and could add incremental revenue over the next year.